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Abstract
Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder with limited approved pharmacological treatment 
options and high symptom burden. Therefore, real-life prescription patterns may differ from guideline recommendations, 
especially in psychiatric inpatient settings. The European Drug Safety Program in Psychiatry (“Arzneimittelsicherheit in der 
Psychiatrie”, AMSP) collects inpatients’ prescription rates cross-sectionally twice a year in German-speaking psychiatric 
hospitals. For this study, the AMSP database was screened for psychiatric inpatients with a primary diagnosis of PTSD 
between 2001 and 2017. N = 1,044 patients with a primary diagnosis of PTSD were identified with 89.9% taking psychotrop-
ics. The average prescription rate was 2.4 (standard deviation: 1.5) psychotropics per patient with high rates of antidepressant 
drugs (72.0%), antipsychotics drugs (58.4%) and tranquilizing drugs (29.3%). The presence of psychiatric comorbidities 
was associated with higher rates of psychotropic drug use. The most often prescribed substances were quetiapine (24.1% of 
all patients), lorazepam (18.1%) and mirtazapine (15.0%). The use of drugs approved for PTSD was low (sertraline 11.1%; 
paroxetine 3.7%). Prescription rates of second-generation antipsychotic drugs increased, while the use of tranquilizing drugs 
declined over the years. High prescription rates and extensive use of sedative medication suggest a symptom-driven prescrip-
tion (e.g., hyperarousal, insomnia) that can only be explained to a minor extent by existing comorbidities. The observed 
discrepancy with existing guidelines underlines the need for effective pharmacological and psychological treatment options 
in psychiatric inpatient settings.
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Introduction
Posttraumatic stress disorder (PTSD) is a psychiatric disor-
der that develops following exposure to a traumatic event 
and is a prevalent reason for inpatient psychiatric admis-
sion. According to the International Classification of Dis-
eases (ICD-10) [1], trauma is defined as a stressful event 
or situation of exceptionally threatening or catastrophic 
nature. In addition, diagnostic criteria of PTSD include 
(1) re-experiencing the traumatic event as intrusive “flash-
backs” or vivid memories, (2) avoidance of trauma-related 
circumstances and (3) increased arousal (“hyperarousal”) 
or psychological sensitivity [1]. Besides these symptoms, 
PTSD is associated with sleep disturbance due to insomnia 
and nightmares [2], anxious and depressed affect, negative 
cognitions and rumination. As a consequence, comorbid 
psychiatric disorders are common in patients with PTSD 
(e.g., depression, anxiety and substance use disorders [3]).
PTSD is a prevalent psychiatric disorder in Germany 
with an estimated 1-month prevalence of 1.3–3.4% [4] and 
a lifetime prevalence of 2.9% [5]. Lifetime prevalence of 
PTSD worldwide ranges between 1.3 and 8.8% [6]. Lifetime 
exposure to a traumatic event seems low in Germany (23.8% 
according to [5]) compared to 70.4% of humans described 
in the WHO World Mental health sample of 24 countries 
(sample includes Germany [7]). Despite exposure to trauma, 
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most people do not develop PTSD following a traumatic 
event [6]. The risk seems to depend on the type of trauma 
with highest risk for developing PTSD after experiencing 
interpersonal violence trauma [7]. Frequency of exposure 
to different types of traumatic events differs between men 
and women with higher prevalence and risk of developing 
PTSD in women [3, 6, 7]. Symptoms of PTSD may be tran-
sient and remit within several weeks or months after the 
traumatic event. However, up to one third of PTSD patients 
has persisting symptoms over 6 years [3].
A variety of psychological and pharmacological treatment 
options are available for PTSD. Currently, trauma-focused 
psychotherapy is recommended as first-line treatment for 
PTSD as it outperforms both non-trauma-focused psycho-
therapy and medication [8]. However, this result has been 
challenged by a recent study with n = 223 participants that 
found no difference between prolonged exposure therapy, 
sertraline with optimized medication enhancement or the 
combination of prolonged exposure therapy with sertraline 
[9]. Psychotropic medication is widely used to support treat-
ment, as trauma-focused psychotherapy is often not suffi-
cient on its own, especially in the beginning, not available 
on the short term or not tolerated [10]. Within a large cohort 
of American Veterans with PTSD observed between 2004 
and 2013, each veteran was prescribed an average of 3.5 psy-
chotropic drugs [11]. The most commonly prescribed drug 
classes in this cohort were antidepressant drugs (81.0%) fol-
lowed by sedative hypnotic drugs including benzodiazepines 
(38.9%), opioids (36.9%), antiepileptic drugs (24.9%) and 
atypical antipsychotic drugs (21.8%). The most common 
antidepressant substances in 2013 in this cohort were ser-
traline (31.2%) and trazodone (29.7% [11]).
Regarding the evidence of pharmacological treatment, 
two meta-analyses found that the use of psychotropic drugs 
was superior to placebo in the treatment of PTSD [10, 12]. 
Whereas fluoxetine, paroxetine and venlafaxine showed a 
small effect compared to placebo regarding clinical symp-
toms, Hoskins et al. [10] found no clear evidence for bro-
maforine, olanzapine, sertraline and topiramate. Using the 
response rate as outcome variable, Gu et al. [12] found an 
effect for fluoxetine, paroxetine and sertraline. Finally, Lee 
et al. [8] describe a small effect for sertraline, venlafaxine 
and nefazodone. There is only insufficient evidence support-
ing the use of most other substances [10], e.g., prazosin/
doxazosin for treating insomnia in PTSD [13, 14]. The use 
of benzodiazepines is even relatively contraindicated despite 
their short-term benefits because of adverse effects (mainly 
addictive potential and rebound symptoms) and may lead to 
a lower success rate of psychotherapy [15].
According to the above-mentioned findings, the German 
guidelines of the “Arbeitsgemeinschaft der Wissenschaftli-
chen Medizinischen Fachgesellschaften e.V.” (AWMF [16]) 
recommend trauma-focused psychotherapy as treatment of 
choice. Pharmacotherapy, not as first-line or sole treatment, 
should consist of sertraline, paroxetine or venlafaxine. How-
ever, in Germany only sertraline and paroxetine are approved 
for the treatment of PTSD. Venlafaxine is recommended in 
case of comorbid depression or anxiety disorder, otherwise 
its “off-label” use has to be stated.
Other existing guidelines such as the NICE guidelines 
(http://www.nice.org.uk/guida nce/ng116 ) similarly recom-
mend selective serotonin reuptake inhibitors (SSRI: ser-
traline, fluoxetine and paroxetine) or venlafaxine, however 
not as first-line treatment. Antipsychotic drugs (such as 
risperidone) are seen as potentially useful for the manage-
ment of PTSD symptoms but should only be an addition to 
psychotherapy.
Despite existing guidelines, discrepancies between the 
recommendations and real-life pharmacological treatment 
of PTSD prevail [17]. This may especially be the case within 
a psychiatric inpatient setting in which patients with par-
ticularly high symptom burden, more comorbidities or pre-
ceding failure of outpatient treatment are treated. Existing 
data is mainly limited to reports of American US veteran 
outpatients. Unfortunately, prescription data among patients 
without combat-induced trauma and outside the US is cur-
rently hardly available. Therefore, the current study aimed to 
assess the actual clinical prescription practice for inpatients 
with PTSD for a broader and more diverse patient collec-
tive better reflecting real-life conditions in German-speaking 
countries. In addition, changes in prescription patterns over 
time were analyzed in order to detect trends that may point 
toward increased awareness of clinical guidelines or effec-
tiveness of specific substances.
Materials and methods
Data source
Data for this study was provided by the European Drug 
Safety Program in Psychiatry (“Arzneimittelsicherheit in 
der Psychiatrie”, AMSP). AMSP is a multicenter drug sur-
veillance program that collects data on (1) drug prescription 
and (2) severe adverse drug reactions in the natural setting 
of routine psychiatric inpatient treatment (for a detailed 
description, see [18, 19]). In brief, AMSP was designed in 
1993 to improve drug safety within the psychiatric inpatient 
setting and to gain insight into the utilization patterns of 
psychotropic drug utilization in psychiatric hospitals. AMSP 
does not interfere with the ongoing treatment. Since 1993, 
the number of participating hospitals that provides data has 
increased. In 2017, 52 psychiatric institutions in Germany, 
Austria and Switzerland contributed to AMSP. Twice a year 
on given reference days, participating institutions record 
drug prescriptions for all psychiatric inpatients currently in 
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treatment. The collected data contains all prescribed psycho-
tropic and non-psychotropic medication (daily dosage) as 
well as sex, age and primary psychiatric diagnosis according 
to the ICD-10. The primary diagnosis is the main reason for 
admission to inpatient treatment. Since 2007, secondary and 
tertiary diagnoses have been additionally assessed. Diagno-
ses are coded by the treating physician under supervision 
of an experienced senior psychiatrist. Data is then trans-
ferred to the anonymized AMSP data bank. Data evalua-
tion and analysis of the AMSP database have been approved 
by both the Ethics Committee of the University of Munich 
and the Ethics Committee of the Hannover Medical School 
(#8100_BO_S_2018).
Study population
All inpatients with a primary diagnosis of PTSD (ICD-
10: F43.1) between 2001 and 2017 were selected from the 
AMSP database. Because PTSD is difficult to diagnose and 
potentially overseen especially when it is not the main rea-
son for hospitalization, analysis was limited to patients with 
a primary diagnosis. 2001 was chosen to guarantee a consist-
ent definition of PTSD criteria due to the implementation 
of ICD-10 and a change of diagnostic criteria compared to 
ICD-9. Data stems from a total of 94 psychiatric hospitals.
Psychotropic medication was classified as following: anti-
depressant drugs, antipsychotic drugs, tranquilizing drugs 
(mostly benzodiazepines), hypnotic drugs (mostly benzodi-
azepine-like drugs, e.g., zopiclone, zolpidem, and the ben-
zodiazepines nitrazepam, flurazepam and lormetazepam), 
antiepileptic drugs, lithium, antiparkinsonian medication 
(mostly biperiden), nootropics and other psychotropic drugs 
(e.g., methylphenidate). Antidepressant drugs were further 
divided into SSRI, selective serotonin noradrenaline reup-
take inhibitors (SSNRI), noradrenergic and specific seroton-
ergic antidepressants (NaSSA) and tricyclic antidepressants 
(TCA). Antipsychotic drugs were grouped into low-potency 
first-generation antipsychotics (FGA), high-potency FGA 
and second-generation antipsychotics (SGA). Furthermore, 
the prescription rate of single drugs is reported for all drugs 
used in > 5% of all patients with PTSD and additionally also 
for paroxetine as one of the approved drugs in Germany, 
Austria and Switzerland.
Data analysis
Data was analyzed with Excel 2019 and SPSS 25.0 (https 
://www.ibm.com/de-de/produ cts/spss-stati stics ). There 
was no missing data. Descriptive data is presented as the 
number of patients taking a specific substance or at least 
one substance within a psychotropic drug group. Percent-
ages refer to the whole sample (including patients without 
medication) if not otherwise specified. The effects of sex 
and comorbidity were analyzed with Chi-squared tests for 
two groups or t tests for independent groups as appropri-
ate. To analyze the effect of age on prescription rates, we 
performed separate logistic regression analyses with age 
as predictor and psychotropic drug groups as dependent 
variable. Finally, we analyzed time trends and performed 
logistic regression analyses with year of prescription as 
predictor to model prescription rates of psychotropic drug 
groups. As the primary focus of this study is on descrip-
tion and modeling, tests of significance were used solely 
in a descriptive way.
Results
Sample
A total of 1,044 inpatients with a primary diagnosis of 
PTSD were identified in the AMSP database, which con-
tains data from a total 147,481 patients. Therefore, PTSD 
patients comprised 0.7% of all patients. Data stems from 
63 psychiatric hospitals in Germany, 13 in Austria and 18 
in Switzerland.
The sample consisted of 329 males (31.5%) and 715 
females (68.5%). Mean age was 37.2 ± 12.8  years with 
a minimum age of 15 and maximum of 94 years. Seven 
patients were younger than 18 years. There was no sig-
nificant mean age difference between men and women 
[t(1042) = 1.57, p = 0.12]. The majority of patients was 
between 21 and 50 years old (74.5%) with 26.7% between 
21 and 30 years, 24.6% between 31 to 40 years and 23.2% 
between 41 and 50 years.
Comorbid psychiatric diagnoses were available as of 2007 
(772 patients with a primary diagnosis of PTSD since 2007) 
with 58.4% of monitored patients suffering from a psychi-
atric comorbidity. Most common psychiatric comorbidities 
alongside a primary diagnosis of PTSD were affective disor-
ders (ICD-10 F3: 27.8%; including 10.8% with major depres-
sive episode, 16.6% with recurrent depressive disorder, and 
0.4% with bipolar affective disorder) followed by personal-
ity disorders (ICD-10 F6: 14.2%; including borderline per-
sonality disorder, BPD: 8.2%) and psychoactive substance 
abuse (ICD-10 F1: 13.6%; including 6.3% with an alcohol 
related disorder; 3.2% sedatives; 2.2% cannabis; 1.3% opioid 
related). Further, 11.3% of patients suffered from a comor-
bid F4 diagnosis (anxiety disorder: 3.4%; dissociative disor-
der: 4.5%; somatoform disorder: 3.1%). A small number of 
patients had comorbid behavioral syndromes (ICD-10 F5: 
3.1%, e.g., eating disorder) or a diagnosis of schizophrenia/
delusional disorder (ICD-10 F2: 2.3%). Women more fre-
quently suffered from a psychiatric comorbidity than men 
[61.2% vs. 53.0%, χ2(1, n = 772) = 4.55, p = 0.03].
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Prescription rates
94.0% of all patients received some type of medication 
(including non-psychotropic drugs) and 89.9% were pre-
scribed at least one psychotropic drug (Table 1). 19.7% 
received one psychotropic drug, 70.2% received two or 
more. The average number of prescribed psychotropics was 
2.4 ± 1.5 per patient. Most commonly prescribed psycho-
tropics per patient were antidepressant drugs (72.0%) and 
antipsychotic drugs (58.4%), followed by tranquilizing 
drugs (29.3%, mainly benzodiazepines), antiepileptic drugs 
(18.4%) and hypnotic drugs (12.3%). The most often pre-
scribed subgroup of antidepressant drugs per patient was 
SSRIs (32.5%), followed by SSNRIs (19.4%), NaSSAs 
(15.2%) and TCAs (14.2%). More patients were prescribed 
SGAs (44.2%) than low-potency FGAs (22.9%) or high-
potency FGAs (5.2%). 19.8% of patients received two or 
more antidepressant drugs (average number of prescribed 
antidepressant drugs: 0.9 ± 0.7). 17.0% received more than 
one antipsychotic drug (average number: 0.8 ± 0.8). Antide-
pressant drugs were most often combined with antipsychotic 
drugs (45.2% of patients), tranquilizing drugs (22.8%) or 
another antidepressant drug (19.8%).
The most frequently prescribed psychotropic drugs were 
quetiapine (24.1% of all patients), lorazepam (18.1%) and 
mirtazapine (15.0%). Table 2 shows the most commonly 
prescribed psychotropics and average daily dose of each 
substance. The rates of the approved drugs sertraline and 
paroxetine were 11.1% and 3.7%, respectively. Doxazosin/
prazosin was prescribed to 15 patients (1.4%).
Men were more likely to be prescribed medication 
than women when including non-psychotropic medica-
tion: 96.7% vs. 92.7% [χ2(1, n = 1044) = 6.14, p = 0.01; 
see Table 1], however, there was no difference regard-
ing the average number of psychotropics [men: 2.3 ± 1.4; 
women: 2.5 ± 1.6, t(1042) = 1.27, p = 0.20]. Male patients 
more often received NaSSAs than women [19.1% vs. 
13.4%, χ2(1, n = 1044) = 5.72, p = 0.02], while TCAs were 
Table 1  Percentage of prescribed drug groups for men and women from 2001 to 2017
SSRI selective serotonin reuptake inhibitor, SSNRI selective serotonin noradrenaline reuptake inhibitors, NaSSA noradrenergic and specific sero-
tonergic antidepressants, TCA tricyclic antidepressants, Other antidepressants: trazodone n = 71, agomelatine n = 31, bupropion n = 14, rebox-
etine n = 3; SGA second-generation antipsychotics, FGA first-generation antipsychotics
*p < 0.05, reported p values are not corrected for multiple comparisons
Total % (n = 1044) Men % (n = 329) Women % (n = 715) χ2(1, n = 1044) p
Any medication 94.0% (981) 96.7% (318) 92.7% (663) 6.14 0.01*
Any psychotropics 89.9% (939) 91.8% (302) 89.1% (637) 1.82 0.18
Antidepressant drugs 72.0% (752) 71.7% (236) 72.2% (516) 0.02 0.88
 SSRI 32.5% (339) 30.7% (101) 33.3% (238) 0.69 0.41
 SSNRI 19.4% (203) 20.4% (67) 19.0% (136) 0.26 0.61
 NaSSA 15.2% (159) 19.1% (63) 13.4% (96) 5.72 0.02*
 TCA 14.2% (148) 10.6% (35) 15.8% (113) 4.94 0.03*
 “Other antidepressants” 11.1% (116) 9.4% (31) 11.9% (85) 1.39 0.24
Antipsychotic drugs 58.4% (610) 59.3% (195) 58.0% (415) 0.14 0.71
 SGA 44.2% (461) 45.9% (151) 43.4% (310) 0.59 0.44
 Low-potency FGA 22.9% (239) 20.1% (66) 24.2% (173) 2.18 0.14
 High-potency FGA 5.2% (54) 5.8% (19) 4.9% (35) 0.36 0.55
Tranquilizing drugs 29.3% (306) 28.6% (94) 29.7% (212) 0.13 0.72
 Benzodiazepines 26.9% (281) 26.4% (87) 27.1% (194) 0.05 0.82
 Tricyclic tranquilizers 1.3% (15) 1.2% (4) 1.5% (11) 0.17 0.68
 Plant-based tranquilizers 0.7% (7) 0.9% (3) 0.6% (4) 0.42 0.52
Hypnotic drugs 12.3% (128) 11.6% (38) 12.6% (90) 0.23 0.64
 Benzodiazepine analogues 8.9% (93) 9.1% (30) 8.8% (63) 0.03 0.87
 Benzodiazepines 1.9% (20) 1.8% (6) 2.0% (14) 0.02 0.88
 Plant-based hypnotics 1.1% (12) 0.9% (3) 1.3% (9) 0.24 0.63
Antiepileptic drugs 18.4% (192) 16.1% (53) 19.4% (139) 1.67 0.20
Lithium 2.4% (25) 0.6% (2) 3.2% (23) 6.56 0.01*
Antiparkinson drugs 2.9% (30) 2.4% (8) 3.1% (22) 0.34 0.56
Nootropics 0.5% (5) 0.9% (3) 0.3% (2) 1.89 0.17
Other psychotropics 1.6% (17) 2.1% (7) 1.4% (10) 0.75 0.39
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more often prescribed to women compared to men [15.8% 
vs. 10.6%, χ2(1, n = 1044) = 4.94, p = 0.03]. In addition, 
women were more frequently treated with lithium [3.2% 
vs 0.6%, χ2(1, n = 1044) = 6.56, p = 0.01].
Patients’ age also affected prescription rates: Logistic 
regression analyses revealed that the prescription rate 
of antidepressant drugs increased with age (B = 0.02, 
SE = 0.01, Wald = 17.87, p < 0.001) with a specifically 
significant increase of SSNRI (B = 0.02, SE = 0.01, 
Wald = 15.00, p < 0.001) and TCA (B = 0.02, SE = 0.01, 
Wald = 5.38, p = 0.02). Age did not affect prescription 
rates of SSRI, NaSSA and “other antidepressant drugs”. 
In addition, prescription of antiepileptic drugs increased 
with age (B = 0.01, SE = 0.01, Wald = 4.14, p = 0.04). In 
contrast, antipsychotic, tranquilizing and hypnotic drugs 
showed neither an increase nor decrease with age. To illus-
trate these findings, Table 3 shows the number of patients 
per age group treated with a substance within the most 
often prescribed drug groups.
Furthermore, we analyzed whether the presence of psy-
chiatric comorbidity was related to prescription rates (see 
Table 4). In general, patients with additional psychiatric 
diagnoses received psychotropic drugs more often than 
patients without psychiatric comorbidity [92.2% vs. 86.0%, 
χ2(1, n = 772) = 7.91, p = 0.005]. By trend, patients with a 
psychiatric comorbidity were more likely to be prescribed 
SSRI [33.0% vs. 27.1%, χ2(1, n = 772) = 3.11, p = 0.08] than 
patients without additional psychiatric diagnoses. Sub-
stances classified as “other antidepressant drugs” (mainly 
trazodone, reboxetine and agomelatine) were more often 
prescribed to patients with psychiatric comorbidity [16.2% 
vs. 10.6%, χ2(1, n = 772) = 4.92, p = 0.03]. Finally, patients 
with comorbid psychiatric diagnosis had higher prescrip-
tion rates of antipsychotic drugs [65.0% vs. 57.9%, χ2(1, 
n = 772) = 3.93, p = 0.04] and lithium [4.2% vs. 1.2%, χ2(1, 
n = 772) = 5.71, p = 0.02].
As 86.0% of patients without comorbidity had psy-
chotropic medication, we further analyzed this subgroup 
(n = 321). Similar to the total sample, this subgroup was 
most often treated with antidepressant drugs (68.6%) and 
antipsychotic drugs (57.9%), followed by tranquilizing 
drugs (27.1%), antiepileptic drugs (16.2%) and hypnotic 
drugs (10.9%; see Table 3). Again, the most frequently pre-
scribed drugs were quetiapine (20.4% of this subgroup), 
lorazepam (12.8%) and mirtazapine (12.4%). Only 2.2% of 
patients took sertraline and 0.0% paroxetine. Thus, 83.8% of 
these patients had psychotropics that were not approved for 
the treatment of PTSD. Regarding sex differences, women 
were more likely to receive hypnotic drugs than men in this 
subgroup [χ2(1, n = 451) = 4.82, p = 0.03]. Finally, logistic 
regression analyses revealed that prescription rates of anti-
depressant drugs increased with age (B = 0.02, SE = 0.01, 
Wald = 4.43, p = 0.04), especially SSRIs (B = 0.02, 
SE = 0.01, Wald = 4.27, p = 0.04). Age did not affect use 
of antipsychotic, tranquilizing, antiepileptic and hypnotic 
drugs.
Time trends
Logistic regression analysis revealed that the overall prescrip-
tion rate of antidepressant drugs per patient remained consist-
ent over time (B = − 0.01, SE = 0.02, Wald = 0.20, p = 0.66). 
Table 2  Prescription rate of the most frequently prescribed psycho-
tropics (> 5% of all patients) for men and women with mean dosage 
and standard deviation
Further included is paroxetine (approved in Germany, Austria and 
Switzerland)
Substance All patients (N = 1044) Mean dosage [mg]
Quetiapine 24.1% (252) 272.4 ± 208.7
Lorazepam 18.1% (189) 2.2 ± 1.8
Mirtazapine 15.0% (157) 30.5 ± 14.9
Venlafaxine 12.7% (133) 185.0 ± 79.7
Sertraline 11.1% (116) 99.1 ± 49.6
Olanzapine 10.0% (104) 11.0 ± 7.1
Escitalopram 8.1% (85) 15.0 ± 6.7
Trazodone 6.8% (71) 149.3 ± 77.9
Citalopram 6.7% (70) 29.8 ± 13.0
Duloxetine 6.3% (66) 85.9 ± 34.6
Risperidone 5.8% (61) 2.5 ± 1.5
Chlorprothixene 5.6% (59) 107.7 ± 151.1
Trimipramine 5.7% (60) 93.6 ± 83.3
Pregabalin 5.2% (54) 270.0 ± 182.5
… … …
Paroxetine 3.7% (39) 32.3 ± 15.8
Table 3  Rates of prescribed 
psychotropic drug groups per 
patient for different age groups
Age group 14–30 (n = 371) 31–40 (n = 257) 41–50 (n = 242) 51–95 (n = 174)
Psychotropics 87.9% (326) 88.3% (227) 93.0% (225) 92.5% (161)
Antidepressant drugs 65.0% (241) 73.5% (189) 75.2% (182) 80.5% (140)
Antipsychotic drugs 58.5% (217) 56.4% (145) 66.1% (160) 50.6% (88)
Antiepileptic drugs 15.1% (56) 16.7% (43) 24.8% (60) 19.0% (33)
Tranquilizing drugs 27.0% (100) 31.1% (80) 33.9% (82) 25.3% (44)
Hypnotic drugs 12.1% (45) 11.7% (30) 14.5% (35) 10.3% (18)
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However, a significant decrease was especially seen for pre-
scription rates of TCAs (B = − 0.07, SE = 0.02, Wald = 13.47, 
p < 0.001). Simultaneously, the prescription of SSNRIs and 
“other antidepressant drugs” significantly increased over time 
(SSNRI: B = 0.08, SE = 0.02, Wald = 18.40, p < 0.001; Other: 
B = 0.14, SE = 0.02, Wald = 31.22, p < 0.001, mainly trazodone 
and agomelatine).The overall prescription rate of antipsychotic 
drugs per patient increased over time (B = 0.05, SE = 0.01, 
Wald = 12.41, p < 0.001) with a significant increase of the 
prescription of SGAs (B = 0.08, SE = 0.01, Wald = 35.21, 
p < 0.001) and a decline of prescription rates of high potency 
FGAs (B = − 0.03, SE = 0.02, Wald = 4.31, p = 0.04). The 
prescription rate of tranquilizing drugs as a group showed a 
decline (B = − 0.04, SE = 0.01, Wald = 7.92, p = 0.005). Hyp-
notic and antiepileptic drugs were consistently prescribed over 
time.
To illustrate time trends, four time periods were created 
(2001–2005: n = 217; 2006–2009: n = 250; 2010–2013: 
n = 240; 2014–2017: n = 337). Figure 1 shows the prescription 
rates of psychotropics (Fig. 1a), subgroups of antidepressant 
drugs (Fig. 1b) and subgroups of antipsychotic drugs (Fig. 1c) 
for the different time periods.
Discussion
This study analyzed pharmacotherapy of 1,044 psychiatric 
inpatients of German-speaking hospitals with the primary 
diagnosis of PTSD. Main result of our study was a high 
prescription rate of psychotropic medication (89.9%) with 
a majority of PTSD patients being prescribed more than 
one psychotropic drug (70.2%), mostly as a combination 
of an antidepressant and antipsychotic drug (45.2%). The 
psychotropic drugs with the highest prescription rates were 
quetiapine, lorazepam and mirtazapine—all of which are 
not approved for the treatment of PTSD in Germany, Aus-
tria and Switzerland. The analysis of time trends revealed 
an increased use of SGAs (mainly quetiapine) and a lower 
prescription rate of tranquilizing drugs over time.
High prescription rates have been observed in inpatients 
with other psychiatric disorders like BPD (90% [20]) and 
adjustment disorder to a similar degree (81.2% [21]). The 
high overall prescription rate of psychotropic drugs may 
seem surprising as psychopharmacotherapy is not rec-
ommended as first-line treatment for PTSD. However, 
Table 4  Prescription rates for patients without or with comorbid psychiatric diagnosis between 2007 and 2017
SSRI selective serotonin reuptake inhibitor, SSNRI selective serotonin noradrenaline reuptake inhibitors, NaSSA noradrenergic and specific sero-
tonergic antidepressants, TCA tricyclic antidepressants, SGA second-generation antipsychotics, FGA first-generation antipsychotics
*p < 0.05,**p < 0.01, reported p values are not corrected for multiple comparisons
All patients (n = 772) Without additional diag-
nosis (n = 321)
With additional diag-
nosis (n = 451)
χ2 (1, n = 772) p
Any medication 94.4% (724) 92.5% (297) 94.7% (427) 1.49 0.22
Any psychotropics 89.6% (692) 86.0% (276) 92.2% (416) 7.91 0.005**
Antidepressant drugs 71.2% (550) 68.6% (220) 73.2% (330) 1.97 0.16
 SSRI 30.6% (236) 27.1% (87) 33.0% (149) 3.11 0.08
 SSNRI 22.8% (176) 22.1% (71) 23.3% (105) 0.14 0.70
 NaSSA 15.0% (116) 17.8% (57) 13.1% (59) 3.21 0.07
 TCA 12.0% (93) 9.3% (30) 14.0% (63) 3.78 0.05
 “Other antidepressants” 13.9% (107) 10.6% (34) 16.2% (73) 4.92 0.03*
Antipsychotic drugs 62.0% (479) 57.9% (186) 65.0% (293) 3.93 0.04*
 SGA 49.0% (378) 46.7% (150) 50.6% (228) 1.10 0.30
 Low-potency FGA 22.5% (174) 20.2% (65) 24.2% (109) 1.65 0.20
 High-potency FGA 4.4% (34) 3.7% (12) 4.9% (22) 0.58 0.45
Tranquilizing drugs 28.1% (217) 27.1% (87) 28.8% (130) 0.28 0.60
Hypnotic drugs 12.2% (94) 10.9% (35) 13.1% (59) 0.83 0.36
Antiepileptic drugs 19.3% (149) 16.2% (52) 21.5% (97) 3.39 0.07
Lithium 3.0% (23) 1.2% (4) 4.2% (19) 5.71 0.02*
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Fig. 1  Time trends for prescrip-
tion rates of a main groups of 
psychotropic drugs, b anti-
depressant drugs: selective 
serotonin reuptake inhibitors 
(SSRI), noradrenergic and 
specific serotonin reuptake 
inhibitors (NaSSA), selec-
tive serotonin noradrenaline 
reuptake inhibitors (SSNRI), 
tricyclic antidepressants (TCA) 
and “other antidepressants” and 
c antipsychotic drugs
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inpatients with PTSD may exhibit high symptom burden 
and higher rates of therapy-resistance that leads to psychi-
atric admission and which may partially explain a more 
frequent use of psychotropics.
The mean number of psychotropics per patient with 
PTSD in this sample was 2.4 and therefore higher than in 
inpatients with adjustment disorder (2.1 per patient [21]) 
but lower than in inpatients with BPD (2.8 per patient [20]). 
The prescription rate in our sample was lower than in a large 
US veteran outpatient sample with PTSD (3.5 per patient 
[11]). However, the cohort described in this study differed 
greatly from our patient collective in regard to multiple fac-
tors like age, sex, comorbidity and symptom burden that 
may have had an impact on the prescription of medication. 
For instance, the veteran’s cohort consisted mainly of men 
(91.5% compared to 31.5% in our sample) with combat-
induced trauma, that were older (average age 49.9 years) 
and suffered from a higher rate of psychiatric comorbid-
ity than patients within our sample that may explain higher 
prescription rates (e.g., affective disorders: 58.9% vs. 27.8% 
in our sample; substance abuse: 33.7% vs. 13.6% [22]). 
Accordingly, we found that prescription rates of antidepres-
sant drugs increased with age in our sample. In contrast, our 
analysis showed only slight differences between men and 
women regarding the use of specific psychotropics. As well, 
types of trauma may differ largely in the veteran population 
compared to our inpatient population.
The presence of an additional psychiatric diagnosis in our 
sample was associated with higher prescription rates of psy-
chotropics, especially antipsychotic and “other antidepres-
sant drugs”. However, this is surprising as only a minority of 
patients with PTSD in this sample suffered from comorbid 
affective (27.8%) and anxiety disorders (3.4%) that explain 
the use of antidepressant drugs. Furthermore, the low rates 
of comorbid schizophrenia and delusional disorders explain 
the extensive use of antipsychotic medication even less. 
Patients without comorbidities in our sample still showed a 
high prescription rate (86.0% psychotropics), with 83.8% of 
patients receiving psychotropic drugs that are not approved 
for the treatment of PTSD.
The prescription of psychotropics seems to be mainly 
symptom-driven with a considerable use of non-approved 
sedative drugs like quetiapine, lorazepam and mirtazapine 
that provide a fast-acting symptom relief. Indeed, hypera-
rousal is a core symptom of PTSD and sleep disorders 
are common due to insomnia and nightmares (e.g., 89% 
prevalence in a US veterans’ sample with PTSD [2]). A 
high symptom burden may even hinder the recommended 
psychotherapeutic treatment and therefore the experience-
based prescription of sedative drugs may enable and support 
psychotherapy.
Models of PTSD suggest that psychotropic medica-
tion may address the PTSD related fear conditioning 
disturbances and stress-related synaptic alterations that 
result from a chronic stress pathology (for a detailed neu-
robiological model, see [23]). However, the exact mecha-
nisms how psychotropic medication leads to a reduction of 
stress pathology and reduction of PTSD symptoms are not 
fully understood. Quetiapine had the highest overall pre-
scription rate in our sample which further increased over 
time. Despite being not approved, SGAs are commonly 
used for patients with anxiety disorder and PTSD [24, 25] 
with an increasing trend [26]. Similarly, increasing rates 
of the prescription of quetiapine have been reported for 
patients with adjustment disorder [21] or BPD [20]. Que-
tiapine is usually well-tolerated without having an addic-
tive potential as compared to benzodiazepines [21]. In 
addition to its sedative effect, quetiapine may prove poten-
tially beneficial in the treatment of PTSD: in a placebo-
controlled trial with 80 patients, Villarreal et al. [27] found 
quetiapine monotherapy given over a period of 12 weeks 
an efficacious treatment, particularly for symptoms like 
re-experiencing, hyperarousal and insomnia. However, the 
observed rate of remission was low [27, 28]. Other authors 
also observed improvement of insomnia [29] and night-
mares [30] under treatment with quetiapine and describe 
anti-suicidal effects [31].
In contrast to the increasing prescription rate of quetia-
pine, the use of lorazepam showed a decline over time in 
our sample. Quetiapine may have been prescribed to control 
symptoms (e.g., arousal, suicidality) in lieu of the use of 
benzodiazepines, which are relatively contraindicated due 
to adverse drug reactions, addictive potential and worsened 
outcome of therapy (for a review, see [15]). However, the 
recommendation to avoid benzodiazepines may be con-
founded as more severely affected patients may both use 
benzodiazepines and profit less from therapy. The prescrip-
tion rate of benzodiazepines within our patient sample were 
similar to US veterans’ samples (30.3% [11]), 14–23% [2]). 
Interestingly, these American samples showed a decline 
in benzodiazepine use over the last years and an increased 
prescription of zolpidem [2, 11], whereas we observed an 
increase of SGAs.
Mirtazapine was prescribed in high rates, however, there 
is limited knowledge about the efficacy of mirtazapine in 
the treatment of PTSD at present [32]. Several smaller 
scale studies suggest a potential effectiveness of mirtazap-
ine as monotherapy [33–37]. The only placebo-controlled 
study with 29 patients found effectiveness on general anxi-
ety symptoms but inconsistent results for different PTSD 
measurements over an 8 weeks observation period [38]. A 
24-week placebo-controlled trial with 36 patients that com-
pared the combination of sertraline and mirtazapine with 
sertraline and placebo showed no significant benefit of the 
combination drug therapy [39]. Regarding our observed pre-
scription patterns, mirtazapine may have been chosen due 
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to its sedative and antidepressant effects in order to treat 
insomnia and affective comorbidities of PTSD.
Prescription rates of approved drugs for PTSD, i.e., ser-
traline and paroxetine, were low within our sample and lower 
than among US veterans [11]. Whereas the prescription rate 
of sertraline was consistent over time, prescription rates of 
paroxetine even showed a decline, possibly in an effort to 
avoid adverse interaction effects of paroxetine by inhibition 
of CYP2D6 [40]. Despite recommendation of paroxetine and 
sertraline by guidelines (for instance German guidelines of 
AWMF [16]), clinicians may decide to prescribe other drugs 
due to their positive experience or due to potentially insuf-
ficient treatment response rates to the recommended drugs.
In general, a multitude of studies have shown that SSRIs 
are an effective treatment for patients suffering from PTSD 
with sertraline, paroxetine and fluoxetine being the most 
studied of this drug class in large caliber studies (for review 
[10, 12]). Further studies exist suggesting that other SSRIs, 
such as citalopram [41, 42] and escitalopram [43, 44] may 
also ameliorate symptoms of PTSD. However, for most of 
these drugs, randomized controlled studies are currently not 
available. Overall, SSRIs are postulated to affect serotoner-
gic activity and modulate fear regulation in PTSD [45]. The 
effects of specific SSRIs may show some variability and the 
response to treatment may be related to trauma type, the 
duration and chronicity of PTSD [46]. Yet, Hoskins et al. 
[10] found insufficient evidence for using different SSRIs for 
different trauma types (combat vs. non-combat).
To summarize, our data shows a discrepancy between 
guidelines and psychiatric real-life prescription rates in 
patients with PTSD. There is a great demand for effec-
tive sedative agents such as mirtazapine and quetiapine for 
PTSD, suggesting that a great deal of suffering of PTSD 
inpatients may be due to hyperarousal and sleep distur-
bances. At the same time, there is a lack of high-quality 
evidence for many drugs that are prescribed under real-life 
conditions due to scarcity of randomized clinical trials. Fur-
ther, the long-term outcome of these drugs in PTSD remains 
unclear. Future research should address the evaluation of 
currently prescribed drugs and the development of new and 
innovative substances by taking into account trauma type 
and comorbidities as this may affect treatment response [11, 
47]. In addition, currently used psychotropics may valuably 
augment psychotherapeutic interventions. Therefore, the 
combination of psychotherapy and pharmacotherapy needs 
to be further studied as there is no clear evidence of an addi-
tional effect of combination therapy [8, 9, 45].
Strength of our study is the large sample of PTSD 
patients with representative comorbidity rates and a repre-
sentative ratio of men and women for PTSD in Germany [5, 
48]. Thus, our obtained data has a high ecological valid-
ity that represents psychopharmacological treatment in the 
natural clinical setting. However, several limitations have 
to be mentioned: our study analyzed prescription rates of 
psychiatric inpatients. This may result in higher prescrip-
tion rates in comparison to outpatients, as inpatients may 
have a higher symptom load and symptom burden and may 
therefore require a more complex treatment. Furthermore, 
in case of medication changes with cross-tapering strate-
gies prescription rates may be overestimated. In addition, 
group differences for sex, age and comorbidities may be 
overestimated as p values were not corrected for multiple 
comparisons. Multiple testing without correction can (inter 
alia) lead to false positive results, thus they have to be inter-
preted very carefully. The clinical severity of PTSD, trauma 
type and number of prior hospitalizations were not assessed 
in this sample. Furthermore, comorbidities may be under-
estimated as we do not have information whether comorbid 
diagnoses were assessed with standardized instruments in 
every contributing hospital. Finally, the available data did 
not include information on concurrent psychotherapy that 
may have interacted with prescription rates. However, the 
rate of psychotherapy can be assumed to be low as the main 
part of the participating psychiatric hospitals are not special-
ized in psychotherapeutic PTSD treatment.
To conclude, our study found that psychiatric inpatients 
with a primary diagnosis of PTSD show high rates of psy-
chotropic drug prescription in clinical routine, particularly of 
sedative drugs like quetiapine and mirtazapine. This can be 
explained only to a minor extent by the presence of psychi-
atric comorbidities and points toward a symptom-oriented 
prescription. The high prescription rates in the absence of 
a comorbidity reveal a discrepancy of actually prescribed 
psychotropics and guideline recommendations that under-
lines the need for better pharmacological and psychologi-
cal treatment strategies for PTSD in particular to address 
hyperarousal and insomnia. More medical trials, especially 
larger scale randomized placebo-controlled double blinded 
studies and naturalistic studies that include patients with 
specific comorbidities, are needed to further improve the 
treatment of PTSD.
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